Editas Medicine/$EDIT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Editas Medicine
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Ticker
$EDIT
Sector
Primary listing
Employees
87
Headquarters
Website
Editas Medicine Metrics
BasicAdvanced
$437m
-
-$1.18
2.14
-
Price and volume
Market cap
$437m
Beta
2.14
52-week high
$4.54
52-week low
$1.66
Average daily volume
3.2m
Financial strength
Current ratio
3.219
Quick ratio
3.174
Long term debt to equity
240.426
Total debt to equity
392.4
Interest coverage (TTM)
-17.71%
Profitability
EBITDA (TTM)
-85.186
Gross margin (TTM)
-109.24%
Net profit margin (TTM)
-281.59%
Operating margin (TTM)
-230.09%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-26.95%
Return on equity (TTM)
-326.07%
Valuation
Price to revenue (TTM)
6.81
Price to book
63.3
Price to tangible book (TTM)
63.3
Price to free cash flow (TTM)
-1.868
Free cash flow yield (TTM)
-53.55%
Free cash flow per share (TTM)
-1.526
Growth
Revenue change (TTM)
7.97%
Earnings per share change (TTM)
-61.25%
3-year revenue growth (CAGR)
19.29%
10-year revenue growth (CAGR)
31.87%
3-year earnings per share growth (CAGR)
-28.20%
10-year earnings per share growth (CAGR)
-20.17%
What the Analysts think about Editas Medicine
Analyst ratings (Buy, Hold, Sell) for Editas Medicine stock.
Editas Medicine Financial Performance
Revenues and expenses
Editas Medicine Earnings Performance
Company profitability
Editas Medicine News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs